Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 388

The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.

18F-FDG PET/CT Imaging In Oncology

Open access
Almuhaideb, Ahmad, Papathanasiou, Nikolaos, Bomanji, Jamshed·2011·Annals of Saudi Medicine
DOI 10.4103/0256-4947.75771
Open this paper in CoChat — free account

Abstract

Accurate diagnosis and staging are essential for the optimal management of cancer patients. Positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) has emerged as a powerful imaging tool for the detection of various cancers. The combined acquisition of PET and CT has synergistic advantages over PET or CT alone and minimizes their individual limitations. It is a valuable tool for staging and restaging of some tumors and has an important role in the detection of recurrence in asymptomatic patients with rising tumor marker levels and patients with negative or equivocal findings on conventional imaging techniques. It also allows for monitoring response to therapy and permitting timely modification of therapeutic regimens. In about 27% of the patients, the course of management is changed. This review provides guidance for oncologists/radiotherapists and clinical and surgical specialists on the use of 18F-FDG PET/CT in oncology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4103/0256-4947.75771

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 85 references

Research works printed but not linked: 53

  1. Yang SK, 2007, The role of PET/CT for evaluating breast cancer, Korean J Radiol, 8, 429, 10.3348/kjr.2007.8.5.429 · doi:10.3348/kjr.2007.8.5.429
  2. Chessin DB, 2005, The emerging role of 18F-fluorodeoxyglucose positron emission tomography in the management of primary and recurrent rectal cancer, J Am Coll Surg, 201, 948, 10.1016/j.jamcollsurg.2005.06.277 · doi:10.1016/j.jamcollsurg.2005.06.277
  3. Even-Sapir E, 2004, Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection, Radiology, 232, 815, 10.1148/radiol.2323031065 · doi:10.1148/radiol.2323031065
  4. Engaras B, 2003, Individual cutoff levels of carcinoembryonic antigen and CA 242 indicate recurrence of colorectal cancer with high sensitivity, Dis Colon Rectum, 46, 313, 10.1007/s10350-004-6548-7 · doi:10.1007/s10350-004-6548-7
  5. Flamen P, 2001, Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: The utility of positron emission tomography (PET), Eur J Cancer, 37, 862, 10.1016/S0959-8049(01)00049-1 · doi:10.1016/s0959-8049(01)00049-1
  6. Simó M, 2002, FDG-PET improves the management of patients with suspected recurrence of colorectal cancer, Nucl Med Commun, 23, 975, 10.1097/00006231-200210000-00007 · doi:10.1097/00006231-200210000-00007
  7. Bassi MC, 2008, FDG-PET/CT imaging for staging and target volume delineation in preoperative conformal radiotherapy of rectal cancer, Int J Radiat Oncol Biol Phys, 70, 1423, 10.1016/j.ijrobp.2007.08.043 · doi:10.1016/j.ijrobp.2007.08.043
  8. Pfau PR, 2007, The role and clinical value of EUS in a multimodality esophageal carcinoma staging program with CT and positron emission tomography, Gastrointest Endosc, 65, 377, 10.1016/j.gie.2006.12.015 · doi:10.1016/j.gie.2006.12.015
  9. Zhang X, 2005, Endoscopic ultrasound for preoperative staging of esophageal carcinoma, Surg Endosc, 19, 1618, 10.1007/s00464-005-0250-2 · doi:10.1007/s00464-005-0250-2
  10. Gan SI, 2007, ASGE Standards of Practice Committee, Role of EUS. Gastrointest Endosc, 66, 425
  11. Yang GY, 2008, The role of positron emission tomography in esophageal cancer, Gastrointest Cancer Res, 2, 3
  12. Yoon YC, 2003, Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection prospective study, Radiology, 227, 764, 10.1148/radiol.2281020423 · doi:10.1148/radiol.2281020423
  13. Luketich JD, 1999, Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans, Ann Thorac Surg, 68, 1133
  14. Heeren PA, 2004, Detection of distant metastases in esophageal cancer with (18)F-FDG PET, J Nucl Med, 45, 980
  15. Moureau-Zabotto L, 2005, Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma, Int J Radiat Oncol Biol Phys, 63, 340, 10.1016/j.ijrobp.2005.02.039 · doi:10.1016/j.ijrobp.2005.02.039
  16. Fleming AJ, 2008, The clinician’s expectations from the use of positron emission tomography/computed tomography scanning in untreated and treated head and neck cancer patients, Curr Opin Otolaryngol Head Neck Surg, 16, 127, 10.1097/MOO.0b013e3282f4939a · doi:10.1097/moo.0b013e3282f4939a
  17. Wang D, 2006, Initial experience of FDG-PET/CT guided IMRT of head-and-neck carcinoma, Int J Radiat Oncol Biol Phys, 65, 143, 10.1016/j.ijrobp.2005.11.048 · doi:10.1016/j.ijrobp.2005.11.048
  18. Fleming AJ, 2007, Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients, Laryngoscope, 117, 1173, 10.1097/MLG.0b013e31805d017b · doi:10.1097/mlg.0b013e31805d017b
  19. Gordin A, 2007, The role of FDG-PET/CT imaging in head and neck malignant conditions: Impact on diagnostic accuracy and patient care, Otolaryngol Head Neck Surg, 137, 130, 10.1016/j.otohns.2007.02.001 · doi:10.1016/j.otohns.2007.02.001
  20. Zanation AM, 2005, Use, accuracy, and implications for patient management of [18F]-2-fluorodeoxyglucose-positron emission/computerized tomography for head and neck tumors, Laryngoscope, 115, 1186, 10.1097/01.MLG.0000163763.89647.9F · doi:10.1097/01.mlg.0000163763.89647.9f
  21. Deantonio L, 2008, FDG-PET/CT imaging for staging and radiotherapy treatment planning of head and neck carcinoma, Radiat Oncol, 3, 29, 10.1186/1748-717X-3-29 · doi:10.1186/1748-717x-3-29
  22. Halpern BS, 2007, Evaluation of suspected local recurrence in head and neck cancer: A comparison between PET and PET/CT for biopsy proven lesions, Eur J Radiol, 62, 199, 10.1016/j.ejrad.2006.11.037 · doi:10.1016/j.ejrad.2006.11.037
  23. Shintani SA, 2008, Utility of PET/CT imaging performed early after surgical resection in the adjuvant treatment planning for head and neck cancer, Int J Radiat Oncol Biol Phys, 70, 322, 10.1016/j.ijrobp.2007.06.038 · doi:10.1016/j.ijrobp.2007.06.038
  24. Silvestri GA, 2003, The noninvasive staging of non-small cell lung cancer: The guidelines, Chest, 123, 147S, 10.1378/chest.123.1_suppl.147S · doi:10.1378/chest.123.1_suppl.147s
  25. Diva F, 2005, Positron emission tomography: Indications in lung cancer - a prospective experience, Rev Port Pneumol, 11, 12
  26. Gupta NC, 2000, Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1 cm), intermediate (1 to 3 cm), and large (>3 cm) lymph node lesions, Chest, 117, 773, 10.1378/chest.117.3.773 · doi:10.1378/chest.117.3.773
  27. Jett JR, 2002, How to optimize staging in early non-small cell lung cancer, Lung cancer, 38, S13, 10.1016/S0169-5002(02)00246-5 · doi:10.1016/s0169-5002(02)00246-5
  28. Kramer H, 2003, Current concepts in the mediastinal lymph node staging of nonsmall cell lung cancer, Ann Surg, 238, 180, 10.1097/01.SLA.0000081086.37779.1a · doi:10.1097/01.sla.0000081086.37779.1a
  29. Al-Sarraf N, 2008, Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography, Eur J Cardiothorac Surg, 33, 104, 10.1016/j.ejcts.2007.09.026 · doi:10.1016/j.ejcts.2007.09.026
  30. van Loon J, 2008, 18FDG-PET based radiation planning of mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: A planning study, Radiother Oncol, 87, 49, 10.1016/j.radonc.2008.02.019 · doi:10.1016/j.radonc.2008.02.019
  31. Joshi SC, 2008, Integrated positron emission tomography/computed tomography fusion imaging: An emerging gold standard in lung cancer, Indian J Cancer, 45, 137, 10.4103/0019-509X.44660 · doi:10.4103/0019-509x.44660
  32. Kiffer JD, 1998, The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer, Lung cancer, 19, 167
  33. Mac Manus MP, 2003, PET scanning in lung cancer: Current status and future directions, Semin Surg Oncol, 21, 149, 10.1002/ssu.10032 · doi:10.1002/ssu.10032
  34. Hellwig D, 2006, Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer, Eur J Nucl Med Mol Imaging, 33, 13, 10.1007/s00259-005-1919-4 · DOI
  35. Lowe V, 1998, Positron emission tomography in lung cancer, Ann Thorac Surg, 65, 1821, 10.1016/S0003-4975(98)00106-4 · doi:10.1016/s0003-4975(98)00106-4
  36. Dhanapathi H, 2007, F-18 FDG PET/PET-CT in the management of lymphoma, Indian J Med Pediatr Oncol, 28, 17, 10.1055/s-0041-1733223 · doi:10.1055/s-0041-1733223
  37. Sandherr M, 2001, Pitfalls in imaging Hodgkin’s disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose, Ann Oncol, 12, 719, 10.1023/A:1011136324038 · doi:10.1023/a:1011136324038
  38. Talbot JN, 2001, [18F]-FDG positron imaging in clinical management of lymphoma patients, Crit Rev Oncol Hematol, 38, 193, 10.1016/S1040-8428(01)00127-5 · doi:10.1016/s1040-8428(01)00127-5
  39. Min JJ, 2001, Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma, Eur J Nucl Med, 28, 639, 10.1007/s002590100509 · doi:10.1007/s002590100509
  40. Horn J, 2006, Routine use of FDG-PET scans in melanoma patients with positive sentinel node biopsy, Eur J Nucl Med Mol Imaging, 33, 887, 10.1007/s00259-006-0077-7 · doi:10.1007/s00259-006-0077-7
  41. Zoller M, 2007, Combined PET/CT in the follow-up of differentiated thyroid carcinoma: What is the impact of each modality.?, Eur J Nucl Med Mol Imaging, 34, 487, 10.1007/s00259-006-0276-2 · doi:10.1007/s00259-006-0276-2
  42. Iagaru A, 2007, F-18 FDG PET/CT in the management of thyroid cancer, Clin Nucl Med, 32, 690, 10.1097/RLU.0b013e318125037a · doi:10.1097/rlu.0b013e318125037a
  43. Zuijdwijk MD, 2008, Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma, Nucl Med Commun, 29, 636, 10.1097/MNM.0b013e3282f813e1 · doi:10.1097/mnm.0b013e3282f813e1
  44. Nakamoto Y, 2005, Positron emission tomography application for gynecologic tumors, Int J Gynecol Cancer, 15, 701, 10.1111/j.1525-1438.2005.00245.x · doi:10.1111/j.1525-1438.2005.00245.x
  45. Basu S, 2009, PET and PET-CT imaging of gynecological malignancies: Present role and future promise, Expert Rev Anticancer Ther, 9, 75, 10.1586/14737140.9.1.75 · doi:10.1586/14737140.9.1.75
  46. Lin WC, 2003, Usefulness of (18)F-fluorodeoxyglucose positron emission tomography to detect para-aortic lymph nodal metastasis in advanced cervical cancer with negative computed tomography findings, Gynecol Oncol, 89, 73, 10.1016/S0090-8258(03)00058-1 · doi:10.1016/s0090-8258(03)00058-1
  47. Belhocine T, 2002, Contribution of whole-body 18FDG PET imaging in the management of cervical cancer, Gynecol Oncol, 87, 90, 10.1006/gyno.2002.6769 · doi:10.1006/gyno.2002.6769
  48. Grigsby PW, 2003, Posttherapy surveillance monitoring of cervical cancer by FDG-PET, Int J Radiat Oncol Biol Phys, 55, 907, 10.1016/S0360-3016(02)04287-6 · doi:10.1016/s0360-3016(02)04287-6
  49. Bristow RE, 2003, Clinically occult ovarian cancer: Patient selection for secondary cytoreductive surgery using combined PET/CT, Gynecol Oncol, 90, 519, 10.1016/S0090-8258(03)00336-6 · doi:10.1016/s0090-8258(03)00336-6
  50. Ho Shona I, 2008, Imaging in cutaneous melanoma, Nucl Med Commun, 29, 847, 10.1097/MNM.0b013e32830439fb · doi:10.1097/mnm.0b013e32830439fb
  51. Havenga K, 2003, Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma, Eur J Surg Oncol, 29, 662, 10.1016/S0748-7983(03)00147-1 · doi:10.1016/s0748-7983(03)00147-1
  52. Bastiaannet E, 2006, Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients, Br J Surg, 93, 243, 10.1002/bjs.5174 · doi:10.1002/bjs.5174
  53. Fulham M, 2007, Impact of FDG PET on the management of patients with suspected or proven metastatic melanoma prior to surgery: A prospective, multi-centre study as part of the Australian PET Data Collection Project. Paper presented at: 54th Annual Meeting of the Society of Nuclear Medicine, Washington, DC

Cited by

See all 388

Metadata

Authors
Almuhaideb, A., Papathanasiou, N., & Bomanji, J.
Venue
Annals of Saudi Medicine
Publisher
King Faisal Specialist Hospital and Research Centre
Published
2011-01
Volume
31
Issue
1
Pages
3-13
ISSN
  • 0256-4947 (ISSN-L)
  • 0975-4466
DOI
10.4103/0256-4947.75771
OpenAlex
W2067213531
Cited by
388
References
85
FWCI
5.06
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 18F-FDG PET/CT Imaging In Oncology. https://app.cochat.ai/papers/10.4103/0256-4947.75771
The paper
Almuhaideb, A., Papathanasiou, N., & Bomanji, J. (2011). 18F-FDG PET/CT Imaging In Oncology. Annals of Saudi Medicine. https://doi.org/10.4103/0256-4947.75771

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.